Clinical trials: Diabetes Type 2
Type 2 Diabetes Mellitus
Study of the Durability of Glycemic Control With Nateglinide
This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.
- Trial name
- NCT00858013
- Testing
- Nateglinide, Glimepiride
- Where
- 7 sites in South Korea
- Volunteers
- 88 people
- Sponsor
- Ajou University School of Medicine
Diabetes
ADA Linagliptin in Long Term Care
This is a study to determine whether glycemic control, as measured by change in HbA1c and frequency of hypoglycemia, is different between treatment with linagliptin (Tradjenta®) and basal insulin in long term care residents(LTC)…
- Trial name
- NCT02061969
- Testing
- linagliptin, insulin glargine
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University
Type 2 Diabetes
Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and…
- Trial name
- NCT01093794
- Testing
- Co-administration of 50 mg sitagliptin and 500 mg metformin, sitagliptin/metformin 50 mg/500 mg tablet, Co-administration of 50 mg sitagliptin and 850 mg metformin
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
- Trial name
- NCT01396161
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
- Trial name
- NCT00849056
- Testing
- albiglutide
- Where
- 331 sites in United States, India and 4 more
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes Mellitus
A multicenter, multinational, randomized,double-blind, placebo-controlled study in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT00804986
- Testing
- LY2428757
- Where
- 60 sites in United States, Austria and 9 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2…
- Trial name
- PIONEER 10 (NCT03015220)
- Testing
- Semaglutide, Dulaglutide
- Where
- 34 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
The goal of this clinical trial is to determine the toxicity and also the efficacy of a treatment that includes the following treatment: Two medications, bortezomib and dexamethasone (or BD), followed by autologous stem cell…
- Conditions
- Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
- Trial name
- NCT01383759
- Testing
- Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Type 2 Diabetes
Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program
This study was conducted to test the possibility of preventing or delaying the development of type 2 diabetes in individuals with impaired glucose tolerance and elevated fasting plasma glucose concentrations by internet-based…
- Trial name
- NCT01085682
- Testing
- Lifestyle counseling, Standard care
- Where
- South Korea
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- The Catholic University of Korea
Type 2 Diabetes Mellitus
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
- Trial name
- NCT00855166
- Testing
- Dapagliflozin, Metformin, Sitagliptin
- Where
- 21 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Dynamically Tailored Behavioral Interventions in Diabetes
In this project, the investigators will evaluate the efficacy of a novel approach to personalizing behavioral interventions for self-management of type 2 diabetes (T2DM) to individuals' behavioral and glycemic profiles discovered…
- Trial name
- NCT04226027
- Testing
- T2.coach
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Columbia University
Diabetic Foot, Foot Ulcer, Diabetic
Use of Santyl in Diabetic Foot Ulcers
This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers…
- Trial name
- NCT02581488
- Testing
- Santyl, Product containing silver
- Where
- 13 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Smith & Nephew, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Usability and Acceptability Study of the P-STEP Mobile Application
Assess the usability and acceptance of the P-STEP app, through allowing participants with specific chronic conditions to pilot the app for 12-weeks.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Coronary Heart Disease
- Trial name
- NCT05830318
- Testing
- P-STEP Mobile Application
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- University of Leicester
Type 2 Diabetes
A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)
This study will assess the pharmacokinetics of two formulations of MK-1006. The primary hypothesis of this study is that the MK-1006 area under the curve (0 to infinity) and maximum concentration after administration of a single…
- Trial name
- NCT00979459
- Testing
- MK-1006 DFC, MK-1006 FCT
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients
In this project the investigators examined the impact of diabetes self-management education using text messaging on increasing awareness of CVD risk perception, dietary intake, physical activity, and diabetes self-management…
- Trial name
- NCT03039569
- Testing
- Text messaging
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of Nebraska Lincoln
Diabetes Mellitus Type 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00800176
- Testing
- RO4998452
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus…
- Trial name
- NCT01650259
- Testing
- OAD, Trazenta
- Where
- Japan
- Volunteers
- 4,876 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi